Biologics

Medicines made from living cells that target specific parts of the immune system to control Crohn's, usually given by injection or drip.

Also called: tnf, biological therapy, biologic drug, monoclonal antibody, biological medicine, mab

Related words immunosuppressant live vaccine biologic anti-tnf adalimumab infliximab biosimilar ustekinumab vedolizumab risankizumab small molecule biologics guselkumab mirikizumab advanced therapy

Topics Biologics and newer medicines

Questions people ask

What is a biologic medicine?

Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.

Sources

Can I have vaccines if I'm on azathioprine, biologics or other immunosuppressants?

Crohn's & Colitis UK says you should not have live vaccines, such as chickenpox, yellow fever or the children's nasal flu vaccine, while on an immunosuppressant. Non-live vaccines, such as the injected flu jab, COVID-19, pneumococcal and the Shingrix shingles vaccine, are safe. The NHS offers Shingrix to adults with a severely weakened immune system. Plan travel vaccines early with your IBD team, because some travel vaccines are live.

Sources

Which biologic is best for Crohn's?

There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.

Sources

Which biologics and targeted medicines are approved for Crohn's on the NHS?

NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.

Sources

What is a biosimilar, and is it as good as the original brand?

A biosimilar is a version of a biologic medicine shown to have no meaningful differences in quality, safety or effectiveness from the original brand. For example, Remicade was the first infliximab and Remsima, Inflectra, Flixabi and Zessly are biosimilars; Humira was the first adalimumab and Amgevita, Hyrimoz, Imraldi, Idacio and Yuflyma are biosimilars. NHS England says switching between them is now accepted practice. A Cochrane review found infliximab and its CT-P13 biosimilar may work similarly.

Sources

Where to read more

Crohn's disease

NHS Web page Dec 2023 For patients

The NHS overview of Crohn's: a lifelong condition where part of the gut becomes inflamed, with no cure yet but treatments that can control it. It lists the usual symptoms, explains that symptoms come and go in flare-ups and remissions, and says there is no single test, so diagnosis usually involves blood and poo tests from the GP followed by camera tests, biopsies and scans in hospital. It also covers possible causes (genes, smoking, a recent stomach bug, recent appendix removal) and when to get urgent help.

Topics About Crohn's disease Symptoms Diagnosis and tests Flare-ups Diet and nutrition Pregnancy and fertility Living well Complications Medicines Surgery

Jargon explained inflammation flare-up remission colonoscopy endoscopy biopsy fistula stricture gastroenterologist inflammatory bowel disease anal fissure perforation nsaids biologics stoma

Postnatal care and breastfeeding

Crohn's & Colitis UK Guide Aug 2025 For patients

Covers looking after yourself after birth and deciding whether breastfeeding is right for you while on Crohn's medicines. It says most biologics are thought to be compatible with breastfeeding, but advice varies by medicine. If you took immune-lowering medicines during pregnancy, your baby's live vaccines may need to be delayed, so tell the baby's healthcare team. Non-live vaccines are thought to be safe.

Topics Pregnancy and fertility Medicines Vaccinations and infections

Jargon explained breastfeeding biologics live vaccine postnatal

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Risankizumab

Crohn's & Colitis UK Guide Jul 2023 For patients

A guide to risankizumab (Skyrizi), a biologic that blocks the IL-23 protein involved in inflammation. You start with a few drips, then have regular injections under the skin; the page explains trial results and side effects.

Topics Biologics and newer medicines

Jargon explained IL-23 interleukin biologic

Biologic medicines and other targeted treatments

Crohn's & Colitis UK Guide Jul 2023 For patients

An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.

Topics Biologics and newer medicines Medicines

Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy

Starting biologic medication

Royal Free London NHS Foundation Trust Leaflet Aug 2025 For patients

A patient leaflet for people starting a biologic for IBD. It explains what biologics are, when they are used (often after steroids or azathioprine have not worked), and lists the biologics used at the hospital, their brands and how each is given.

Topics Biologics and newer medicines

Jargon explained biologic infusion biosimilar

Biosimilar medicines

NHS England Web page Patients and professionals

NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.

Topics Biologics and newer medicines Medicines

Jargon explained biosimilar originator medicine switching

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis

Cochrane Systematic review Jun 2026 Patients and professionals

An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.

Topics Biologics and newer medicines Research

Jargon explained network meta-analysis relative risk number needed to treat biosimilar

Search everything for "biologics"